AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2804253
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of test or reference drug
Trial: 2804253
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of test or reference drug
Trial: 2804253
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of phenytoin
Trial: 2804253
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of phenytoin
Trial: 985661
Drug: Tobramycin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 1.5 mg/kg or 80 mg administered via rapid intravenous injection
Trial: 985661
Drug: Tobramycin dosage
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin dosage interval of 6 hr with a total dosage of 6 mg/kg per day
Trial: 30444982
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel (20 mL of 2% lidocaine gel)
Trial: 28692301
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Trial: 21135313
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with citalopram followed by up to 3 sequential next‐step treatments.
Trial: 11240973
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg twice a day for 7 days) + Mexiletine (200 mg on the eighth day)
Trial: 11240973
Drug: Mexiletine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (200 mg alone)
Trial: 7755478
Drug: Cilazapril (CIL)
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (CIL) 10 mg per day (n=6)
Trial: 2790919
Drug: Hydroxychloroquine sulphate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulphate, 20 mg/day for one year
Trial: 1255309
Drug: Chloramphenicol treatment
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol treatment
Trial: 30678744
Drug: Individual psychological
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual psychological treatments (Healthy Activity Program for depression)
Trial: 12908854
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily and caffeine 100 mg three times daily
Trial: 12908854
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily and caffeine 100 mg three times daily
Trial: 12799847
Drug: Tilidine/naloxone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine/naloxone 50 mg
Trial: 12799847
Drug: Tilidine/naloxone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine/naloxone 100 mg
Trial: 12799847
Drug: Codeine 100
RxNorm normalized name: codeine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 100 mg
Trial: 12799847
Drug: Tilidine/naloxone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine/naloxone 50 mg and 100 mg
Trial: 12799847
Drug: Codeine 50
RxNorm normalized name: codeine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 50 mg and 100 mg
Trial: 1829465
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day acitretin
Trial: 1829465
Drug: Acitretin therapy
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin therapy after placebo
Trial: 25243325
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg od
Trial: 25243325
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg od
Trial: 16442114
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with estradiol +/- medroxyprogesterone
Trial: 14579993
Drug: High starting
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High starting dose: 1 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Trial: 14579993
Drug: Low starting
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low starting dose: 0.25 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Trial: 1283931
Drug: Local, laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local, laparoscopic Prostaglandin‐injection
Trial: 30482661
Drug: Bladder-sparing tri-modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder-sparing tri-modality therapy (TMT)
Trial: 29505578
Drug: DOT (Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOT (Directly Observed Treatment)
Trial: 29505578
Drug: NDOT (Non-Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDOT (Non-Directly Observed Treatment)
Trial: 24518370
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg or 1600 μg of salbutamol
Trial: 20016461
Drug: AKL-0707 (GH-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKL-0707 (GH-releasing hormone super-agonist)
Trial: 17401781
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose 12.3 mg/day)
Trial: 17401781
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 5.2 mg/day)
Trial: 7756097
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) formulation (100 mg levodopa/25 mg genserazide)
Trial: 7756097
Drug: Controlled Release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release (CR) formulation (300 mg levodopa/75 mg benserazide)
Trial: 7465474
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of glucose a day
Trial: 7465474
Drug: 129 g
RxNorm normalized name: Xenon Xe 129 Gas Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 129 g of glucose a day
Trial: 30644570
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of mirabegron (50 mg) and solifenacin (5 mg)
Trial: 30644570
Drug: Solifenacin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin monotherapy
Trial: 30644570
Drug: Mirabegron monotherapy
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron monotherapy
Trial: 27830922
Drug: Psychomotor treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor treatment (group A)
Trial: 15271731
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine 150 microg diluted with 9 mL of normal saline 30 min before surgery and PCEA with morphine (0.1 mg/mL) and clonidine (1.5 microg/mL) in 0.2% ropivacaine 100 mL after surgery
Trial: 15271731
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 mL before surgery and PCEA with morphine and ropivacaine after surgery
Trial: 11563588
Drug: Novel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatment strategies (nonmyeloablative allogeneic transplantation, vaccination)
Trial: 8513525
Drug: Ondansetron (antiemetic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (antiemetic, selective serotonin 5-HT3 receptor antagonist) administered via rapid intravenous infusion over two minutes.
Trial: 8513525
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) administered via rapid intravenous infusion.
Trial: 14591143
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Suloctidil daily
Trial: 14591143
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg Suloctidil daily
Trial: 17688420
Drug: Normal-sodium diet
RxNorm normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-sodium diet (120 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Trial: 17688420
Drug: Low-sodium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium diet (80 mmol sodium) plus oral furosemide [250‐500 mg, b.i.d.]
Trial: 10350104
Drug: Subgroup 1
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup 1 (TnT peak < 1 ng/ml)
Trial: 10350104
Drug: Subgroup 2
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup 2 (TnT peak between 1 and 3 ng/ml)
Trial: 10350104
Drug: Subgroup 3
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup 3 (TnT peak > 3 ng/ml)
Trial: 7859141
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 600 mg/day plus acyclovir (ACV) 4,800 mg orally per day
Trial: 7859141
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 600 mg/day plus placebo
Trial: 1838032
Drug: Cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5 mg once daily)
Trial: 7171073
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy (MMTP)
Trial: 6423586
Drug: Naloxone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone infusion (0.4 mg/ml saline)
Trial: 6423586
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline infusion 1 ml)
Trial: 6423586
Drug: Placebo (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (infusion control)
Trial: 27143669
Drug: Universal decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal decolonization treatment with chlorhexidine bathing and nasal mupirocin
Trial: 22571408
Drug: Neridronate 100
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neridronate 100 mg intravenously every 90 days
Trial: 22571408
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (500 mg calcium with 400 iu vitamin D daily)
Trial: 12423628
Drug: Acipimox (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (an inhibitor of lipolysis) with GH
Trial: 9862828
Drug: L‐NMMA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 2 mg/kg/h
Trial: 9862828
Drug: L‐NMMA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 4 mg/kg/h
Trial: 9862828
Drug: L‐NMMA 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 0.5 mg/kg/h
Trial: 7537524
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of all-trans retinoic acid (ATRA) and granulocyte-colony stimulating factor (G-CSF)
Trial: 7537524
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of ATRA, G-CSF, erythropoietin (Epo), and tocopherol
Trial: 7537524
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of ATRA and cytokines
Trial: 7033013
Drug: Sulphadiazine/trimethoprim (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphadiazine/trimethoprim (1 g daily for 10 days)
Trial: 7033013
Drug: Sulphamethoxazole/trimethoprim (1.92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphamethoxazole/trimethoprim (1.92 g B.I.D for 10 days)
Trial: 29605360
Drug: Intraoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative treatment with paracetamol
Trial: 27468022
Drug: Epinephrine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.1 mg/kg i.m.)
Trial: 27468022
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (0.9% saline, at 0.1 ml/kg i.m.)
Trial: 23184162
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of fluoride gel using a toothbrush
Trial: 23184162
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of fluoride gel using a tray (control)
Trial: 17397734
Drug: Stromal hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stromal hydration (using fortified balanced salt solution [BSS Plus])
Trial: 25782693
Drug: Home-based telemonitored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based telemonitored robotic-assisted therapy (HMP) combined with home exercise program (HEP) for 3 hours/day, 5 days/week for 8 weeks
Trial: 25782693
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise program (HEP) only at identical dosage
Trial: 19514485
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (close reduction and immobilization in a plastofit splint)
Trial: 19514485
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (percutaneous fixation by Kirschner‐wires)
Trial: 16705315
Drug: KSHV latent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KSHV latent antibodies
Trial: 16705315
Drug: KSHV lytic
RxNorm normalized name: Fytic acid
DrugBank: Phytic acid (DB14981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KSHV lytic antibodies
Trial: 16705315
Drug: Anti-EBV antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-EBV antibodies
Trial: 16705315
Drug: Antibody levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody levels against EBV
Trial: 16705315
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against KSHV (latent and lytic)
Trial: 15298070
Drug: Newer generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer generation antidepressants
Trial: 9401312
Drug: Serotonergic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic agents
Trial: 8260542
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered immunoglobulins (IVIG)
Trial: 8260542
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IVIG treatment)
Trial: 22689290
Drug: Transcranial Magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Magnetic Stimulation (TMS) taper
Trial: 22689290
Drug: Continuation pharmacotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation pharmacotherapy or naturalistic follow-up after TMS taper
Trial: 20367092
Drug: Fully etched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully etched test implants
Trial: 20367092
Drug: Hybrid control
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid control implants
Trial: 18723908
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 0.5 g/kg (low dose group)
Trial: 18723908
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 1.0 g/kg (high dose group)
Trial: 18723908
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (0.5 g/kg and 1.0 g/kg)
Trial: 8739021
Drug: Squalene 860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squalene 860 mg
Trial: 8739021
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin 10 mg + Squalene 860 mg)
Trial: 3700343
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lecithin and ergoloid mesylates
Trial: 26969660
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (loading dose with 50 mg/kg over 10 min and then 15 mg/kg/h by continuous infusion)
Trial: 21834964
Drug: Ongoing information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing information as to the natural history of the condition and treatment as usual
Trial: 19350305
Drug: Long-term chemoradiotherapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term chemoradiotherapy (RT/CTx) as standard treatment for locally advanced rectal cancer.
Trial: 19350305
Drug: Quality controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality controlled principles of radical surgery (partial vs total mesorectal excision) followed by adjuvant chemotherapy.
Trial: 17352947
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation for 8 weeks
Trial: 17352947
Drug: Baseline (pre-treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (pre-treatment)
Trial: 15122749
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated 8 weeks after onset of acute hepatitis.
Trial: 15122749
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, followed by interval IFN therapy (3 times weekly for 20 weeks).
Trial: 15122749
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated after 1 year of observation.
Trial: 9257777
Drug: grepafloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: grepafloxacin (400 mg)
Trial: 9257777
Drug: cefixime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefixime (400 mg)
Trial: 24411489
Drug: Intervention Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Formula (IF) - 1.89 g protein/100 kcal with α‐lactalbumin (ALAB) and LC‐PUFA
Trial: 24411489
Drug: Control Formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Formula (CF) - 2.30 g protein/100 kcal with standard whey and no LC‐PUFA
Trial: 18942247
Drug: Lactated ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated ringer 20 ml/kg
Trial: 18942247
Drug: 5% hypertonic
RxNorm normalized name: Walgreens Sodium Chloride 5% Hypertonicity Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% hypertonic saline 4 ml/kg followed by lactated ringer 10 ml/kg/hr